<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments for Biotechnology Patent Law Blog | Patents4Life by Warren Woessner</title>
	<atom:link href="http://www.patents4life.com/comments/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.patents4life.com</link>
	<description></description>
	<lastBuildDate>Mon, 05 Dec 2011 15:41:30 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.4</generator>
	<item>
		<title>Comment on HUMAN GENOME SCIENCES v. ELI LILLY – Increased European Harmony? by Steve Blance</title>
		<link>http://www.patents4life.com/2011/12/human-genome-sciences-v-eli-lilly-%e2%80%93-increased-european-harmony/comment-page-1/#comment-15378</link>
		<dc:creator>Steve Blance</dc:creator>
		<pubDate>Mon, 05 Dec 2011 15:41:30 +0000</pubDate>
		<guid isPermaLink="false">http://www.patents4life.com/?p=1657#comment-15378</guid>
		<description>A full paper on this topic by Avidity IP will appear in the 30th Anniversary edition of Biotechnology Law Review to be released in January 2012 and will provide additional narrative and opinion on this subject (a synopsis published on November 4, 2011 is available at http://www.avidity-ip.com/news/add-news-item/hgs-v-eli-lilly the full BLR article will be published as an Avidity web version at www.avidity-ip.com).</description>
		<content:encoded><![CDATA[<p>A full paper on this topic by Avidity IP will appear in the 30th Anniversary edition of Biotechnology Law Review to be released in January 2012 and will provide additional narrative and opinion on this subject (a synopsis published on November 4, 2011 is available at <a href="http://www.avidity-ip.com/news/add-news-item/hgs-v-eli-lilly" rel="nofollow">http://www.avidity-ip.com/news/add-news-item/hgs-v-eli-lilly</a> the full BLR article will be published as an Avidity web version at <a href="http://www.avidity-ip.com" rel="nofollow">http://www.avidity-ip.com</a>).</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on Powell v. Home Depot – False Petition Not “Egregious Misconduct” by Lynn Tyler</title>
		<link>http://www.patents4life.com/2011/11/powell-v-home-depot-%e2%80%93-false-petition-not-%e2%80%9cegregious-misconduct%e2%80%9d/comment-page-1/#comment-15136</link>
		<dc:creator>Lynn Tyler</dc:creator>
		<pubDate>Thu, 17 Nov 2011 13:43:39 +0000</pubDate>
		<guid isPermaLink="false">http://www.patents4life.com/?p=1627#comment-15136</guid>
		<description>Although it is only one panel and thus too early to tell, it would seem patent owners should welcome this case because it shows TheraSense has some teeth. In contrast to the prior law as reflected in Scanner Tech., and quoted above, the statements in the Petition to Make Special in this case were essentially irrelevant. They may have affected how soon the PTO granted the patent, but not whether it did so and thus were not &quot;but-for&quot; material under TheraSense. Because they were supposedly true when made, there was no &quot;affirmative egregious misconduct&quot; in failing to correct them once they became false.

Actually, given the facts recited in the Federal Circuit&#039;s opinion, I wonder if Home Depot would have been better off to argue that they were not even true when made. As I understand it, the statements were that Powell was obligated to supply the patented invention at a time there was no contract with Home Depot. The statements appear to have been based on an expectation arising out of an existing relationship, not a contract.</description>
		<content:encoded><![CDATA[<p>Although it is only one panel and thus too early to tell, it would seem patent owners should welcome this case because it shows TheraSense has some teeth. In contrast to the prior law as reflected in Scanner Tech., and quoted above, the statements in the Petition to Make Special in this case were essentially irrelevant. They may have affected how soon the PTO granted the patent, but not whether it did so and thus were not &#8220;but-for&#8221; material under TheraSense. Because they were supposedly true when made, there was no &#8220;affirmative egregious misconduct&#8221; in failing to correct them once they became false.</p>
<p>Actually, given the facts recited in the Federal Circuit&#8217;s opinion, I wonder if Home Depot would have been better off to argue that they were not even true when made. As I understand it, the statements were that Powell was obligated to supply the patented invention at a time there was no contract with Home Depot. The statements appear to have been based on an expectation arising out of an existing relationship, not a contract.</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on Powell v. Home Depot – False Petition Not “Egregious Misconduct” by Lynn Tyler</title>
		<link>http://www.patents4life.com/2011/11/powell-v-home-depot-%e2%80%93-false-petition-not-%e2%80%9cegregious-misconduct%e2%80%9d/comment-page-1/#comment-15108</link>
		<dc:creator>Lynn Tyler</dc:creator>
		<pubDate>Tue, 15 Nov 2011 21:45:28 +0000</pubDate>
		<guid isPermaLink="false">http://www.patents4life.com/?p=1627#comment-15108</guid>
		<description>Interesting. In Scanner Technologies Corp. v. Icos Vision Systems Corp. N.V., 528 F.3d 1365, 1375 (Fed. Cir. 2008), there were false statements in a petition to make special and the Federal Circuit wrote: &quot;We reaffirm that a false statement that succeeds in expediting the application is, as a matter of law, material for purposes of assessing the issue of inequitable conduct.&quot; I&#039;ll have to read the case to see all the facts to decide if I think the decision was right or not given that apparently the statement was true when made.</description>
		<content:encoded><![CDATA[<p>Interesting. In Scanner Technologies Corp. v. Icos Vision Systems Corp. N.V., 528 F.3d 1365, 1375 (Fed. Cir. 2008), there were false statements in a petition to make special and the Federal Circuit wrote: &#8220;We reaffirm that a false statement that succeeds in expediting the application is, as a matter of law, material for purposes of assessing the issue of inequitable conduct.&#8221; I&#8217;ll have to read the case to see all the facts to decide if I think the decision was right or not given that apparently the statement was true when made.</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on EU High Court Bans Patents on Cells Requiring Processing Human Embryos by IPPractice.ca - EU Court of Justice limits patentability of embryonic research</title>
		<link>http://www.patents4life.com/2011/10/eu-high-court-bans-patents-on-cells-requiring-processing-human-embryos/comment-page-1/#comment-14712</link>
		<dc:creator>IPPractice.ca - EU Court of Justice limits patentability of embryonic research</dc:creator>
		<pubDate>Wed, 19 Oct 2011 00:33:24 +0000</pubDate>
		<guid isPermaLink="false">http://www.patents4life.com/?p=1542#comment-14712</guid>
		<description>[...] commentary on the ruling is available from several sources, including the WSJ Blog, and Patents4Life blog among [...]</description>
		<content:encoded><![CDATA[<p>[...] commentary on the ruling is available from several sources, including the WSJ Blog, and Patents4Life blog among [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on Obviousness = Equivalence? Saint-Gobain v. Siemens by Infringement by Unobvious Changes – A Look (Way) Back &#124; Biotechnology Patent Law Blog &#124; Patents4Life by Warren Woessner</title>
		<link>http://www.patents4life.com/2011/10/obviousness-equivalence-saint-gobain-v-siemens/comment-page-1/#comment-14641</link>
		<dc:creator>Infringement by Unobvious Changes – A Look (Way) Back &#124; Biotechnology Patent Law Blog &#124; Patents4Life by Warren Woessner</dc:creator>
		<pubDate>Mon, 17 Oct 2011 01:47:27 +0000</pubDate>
		<guid isPermaLink="false">http://www.patents4life.com/?p=1518#comment-14641</guid>
		<description>[...] See my previous post on Saint-Gobain. [...]</description>
		<content:encoded><![CDATA[<p>[...] See my previous post on Saint-Gobain. [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on Classen Immunotherapeutics v. Biogen Idec: Corrected Opinion Likely? by EG</title>
		<link>http://www.patents4life.com/2011/09/classen-immunotherapeutics-v-biogen-idec-corrected-opinion-likely/comment-page-1/#comment-13921</link>
		<dc:creator>EG</dc:creator>
		<pubDate>Thu, 08 Sep 2011 12:20:12 +0000</pubDate>
		<guid isPermaLink="false">http://www.patents4life.com/?p=1365#comment-13921</guid>
		<description>Warren,

The distinction made by the majority between the claims in the &#039;739/&#039;139 patents and the claims in the &#039;283 patent is reasonable.  (I&#039;m also not going to dwell on the other problems with the claims in the &#039;739/&#039;139 patents, including the &quot;may&quot; language which raises potentially both 35 USC 101 and 35 USC 112, second paragraph, issues.)  The &quot;comparative&quot; claims in the &#039;283 patent are problematic under 35 USC 101 as process/method claims because there&#039;s no &quot;end result&quot; achieved or even a suggestion of what to do after the &quot;comparison&quot; is made.  Even under the now discarded (and more objective) &quot;tangible, concrete, and useful result&quot; test, the claims in the &#039;283 patent would fail because there&#039;s no &quot;end result&quot; either explicitly or implicitly achieved by the claimed method.  Let&#039;s face it, the claims in all three of these patents are badly written method claims.</description>
		<content:encoded><![CDATA[<p>Warren,</p>
<p>The distinction made by the majority between the claims in the &#8217;739/&#8217;139 patents and the claims in the &#8217;283 patent is reasonable.  (I&#8217;m also not going to dwell on the other problems with the claims in the &#8217;739/&#8217;139 patents, including the &#8220;may&#8221; language which raises potentially both 35 USC 101 and 35 USC 112, second paragraph, issues.)  The &#8220;comparative&#8221; claims in the &#8217;283 patent are problematic under 35 USC 101 as process/method claims because there&#8217;s no &#8220;end result&#8221; achieved or even a suggestion of what to do after the &#8220;comparison&#8221; is made.  Even under the now discarded (and more objective) &#8220;tangible, concrete, and useful result&#8221; test, the claims in the &#8217;283 patent would fail because there&#8217;s no &#8220;end result&#8221; either explicitly or implicitly achieved by the claimed method.  Let&#8217;s face it, the claims in all three of these patents are badly written method claims.</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on Classen Immunotherapeutics v. Biogen Idec: Corrected Opinion Likely? by Patent Baristas &#187; Moore Dissent in Classen</title>
		<link>http://www.patents4life.com/2011/09/classen-immunotherapeutics-v-biogen-idec-corrected-opinion-likely/comment-page-1/#comment-13916</link>
		<dc:creator>Patent Baristas &#187; Moore Dissent in Classen</dc:creator>
		<pubDate>Wed, 07 Sep 2011 16:32:46 +0000</pubDate>
		<guid isPermaLink="false">http://www.patents4life.com/?p=1365#comment-13916</guid>
		<description>[...] Woessner of Patents4Life viewed the discrepancy thusly: At best, this is a complete misreading of claim 1 of the ‘283 [...]</description>
		<content:encoded><![CDATA[<p>[...] Woessner of Patents4Life viewed the discrepancy thusly: At best, this is a complete misreading of claim 1 of the ‘283 [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on Classen Immunotherapeutics v. Biogen Idec: Corrected Opinion Likely? by Rodney</title>
		<link>http://www.patents4life.com/2011/09/classen-immunotherapeutics-v-biogen-idec-corrected-opinion-likely/comment-page-1/#comment-13906</link>
		<dc:creator>Rodney</dc:creator>
		<pubDate>Tue, 06 Sep 2011 12:29:57 +0000</pubDate>
		<guid isPermaLink="false">http://www.patents4life.com/?p=1365#comment-13906</guid>
		<description>I would not have predicted that.  I didn&#039;t think Moore would get it right, and I sure didn&#039;t think Rader and Newman, particularly Newman, would get it wrong.</description>
		<content:encoded><![CDATA[<p>I would not have predicted that.  I didn&#8217;t think Moore would get it right, and I sure didn&#8217;t think Rader and Newman, particularly Newman, would get it wrong.</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on AMC v. Myriad – “Laws of Nature” Exception Does Not Include Isolated DNA by Wegner Paper Probes Myriad Decisions Flaws &#124; Biotechnology Patent Law Blog &#124; Patents4Life by Warren Woessner</title>
		<link>http://www.patents4life.com/2011/07/amc-v-myriad-%e2%80%93-%e2%80%9claws-of-nature%e2%80%9d-exception-does-not-include-isolated-dna/comment-page-1/#comment-13652</link>
		<dc:creator>Wegner Paper Probes Myriad Decisions Flaws &#124; Biotechnology Patent Law Blog &#124; Patents4Life by Warren Woessner</dc:creator>
		<pubDate>Tue, 02 Aug 2011 21:40:04 +0000</pubDate>
		<guid isPermaLink="false">http://www.patents4life.com/?p=1334#comment-13652</guid>
		<description>[...] in the legal reasoning behind the holding in the recent AMC v. Myriad decision. [See my post of July 31st 2011 on the decision]. (Prof. Hegner’s paper is attached at the end of this post.) To summarize, [...]</description>
		<content:encoded><![CDATA[<p>[...] in the legal reasoning behind the holding in the recent AMC v. Myriad decision. [See my post of July 31st 2011 on the decision]. (Prof. Hegner’s paper is attached at the end of this post.) To summarize, [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on Inequitable Conduct in Canada – Disarming the “Atomic Bomb” by Intellectual Property</title>
		<link>http://www.patents4life.com/2011/07/inequitable-conduct-in-canada-%e2%80%93-disarming-the-%e2%80%9catomic-bomb%e2%80%9d/comment-page-1/#comment-13549</link>
		<dc:creator>Intellectual Property</dc:creator>
		<pubDate>Tue, 26 Jul 2011 08:58:03 +0000</pubDate>
		<guid isPermaLink="false">http://www.patents4life.com/?p=1301#comment-13549</guid>
		<description>This decision sends a strong signal about the importance of protecting intellectual property in Canada.</description>
		<content:encoded><![CDATA[<p>This decision sends a strong signal about the importance of protecting intellectual property in Canada.</p>
]]></content:encoded>
	</item>
</channel>
</rss>

